View in EDS

280P Efficacy of avelumab + axitinib (A + Ax) vs sunitinib (S) by number of IMDC risk factors in patients (pts) with advanced renal cell carcinoma (aRCC): Subgroup analyses from the final analysis of the phase III JAVELIN renal 101 trial.

Saved in:
Bibliographic Details
Title: 280P Efficacy of avelumab + axitinib (A + Ax) vs sunitinib (S) by number of IMDC risk factors in patients (pts) with advanced renal cell carcinoma (aRCC): Subgroup analyses from the final analysis of the phase III JAVELIN renal 101 trial.
Authors: Eto, M.1 (AUTHOR), Motzer, R.J.2 (AUTHOR), Choueiri, T.K.3 (AUTHOR), Haanen, J.B.A.G.4 (AUTHOR), Oya, M.5 (AUTHOR), Uemura, H.6 (AUTHOR), Venugopal, B.7 (AUTHOR), Rini, B.I.8 (AUTHOR), Miyake, H.9 (AUTHOR), Albiges, L.10 (AUTHOR), Schmidinger, M.11 (AUTHOR), Tomita, Y.12 (AUTHOR), Umeyama, Y.13 (AUTHOR), Ellers-Lenz, B.14 (AUTHOR), Hoffman, J.15 (AUTHOR), Larkin, J.16 (AUTHOR)
Source: Annals of Oncology. 2024 Supplement 4, Vol. 35, pS1512-S1513. 2p.
Database: Academic Search Ultimate
FullText Text:
  Availability: 0
Header DbId: asn
DbLabel: Academic Search Ultimate
An: 181112520
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: 280P Efficacy of avelumab + axitinib (A + Ax) vs sunitinib (S) by number of IMDC risk factors in patients (pts) with advanced renal cell carcinoma (aRCC): Subgroup analyses from the final analysis of the phase III JAVELIN renal 101 trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Eto%2C+M%2E%22">Eto, M.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Motzer%2C+R%2EJ%2E%22">Motzer, R.J.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Choueiri%2C+T%2EK%2E%22">Choueiri, T.K.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Haanen%2C+J%2EB%2EA%2EG%2E%22">Haanen, J.B.A.G.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Oya%2C+M%2E%22">Oya, M.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Uemura%2C+H%2E%22">Uemura, H.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Venugopal%2C+B%2E%22">Venugopal, B.</searchLink><relatesTo>7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Rini%2C+B%2EI%2E%22">Rini, B.I.</searchLink><relatesTo>8</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Miyake%2C+H%2E%22">Miyake, H.</searchLink><relatesTo>9</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Albiges%2C+L%2E%22">Albiges, L.</searchLink><relatesTo>10</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Schmidinger%2C+M%2E%22">Schmidinger, M.</searchLink><relatesTo>11</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Tomita%2C+Y%2E%22">Tomita, Y.</searchLink><relatesTo>12</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Umeyama%2C+Y%2E%22">Umeyama, Y.</searchLink><relatesTo>13</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ellers-Lenz%2C+B%2E%22">Ellers-Lenz, B.</searchLink><relatesTo>14</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hoffman%2C+J%2E%22">Hoffman, J.</searchLink><relatesTo>15</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Larkin%2C+J%2E%22">Larkin, J.</searchLink><relatesTo>16</relatesTo> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. 2024 Supplement 4, Vol. 35, pS1512-S1513. 2p.
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=181112520
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.annonc.2024.10.300
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 2
        StartPage: S1512
    Titles:
      – TitleFull: 280P Efficacy of avelumab + axitinib (A + Ax) vs sunitinib (S) by number of IMDC risk factors in patients (pts) with advanced renal cell carcinoma (aRCC): Subgroup analyses from the final analysis of the phase III JAVELIN renal 101 trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Eto, M.
      – PersonEntity:
          Name:
            NameFull: Motzer, R.J.
      – PersonEntity:
          Name:
            NameFull: Choueiri, T.K.
      – PersonEntity:
          Name:
            NameFull: Haanen, J.B.A.G.
      – PersonEntity:
          Name:
            NameFull: Oya, M.
      – PersonEntity:
          Name:
            NameFull: Uemura, H.
      – PersonEntity:
          Name:
            NameFull: Venugopal, B.
      – PersonEntity:
          Name:
            NameFull: Rini, B.I.
      – PersonEntity:
          Name:
            NameFull: Miyake, H.
      – PersonEntity:
          Name:
            NameFull: Albiges, L.
      – PersonEntity:
          Name:
            NameFull: Schmidinger, M.
      – PersonEntity:
          Name:
            NameFull: Tomita, Y.
      – PersonEntity:
          Name:
            NameFull: Umeyama, Y.
      – PersonEntity:
          Name:
            NameFull: Ellers-Lenz, B.
      – PersonEntity:
          Name:
            NameFull: Hoffman, J.
      – PersonEntity:
          Name:
            NameFull: Larkin, J.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 02
              M: 12
              Text: 2024 Supplement 4
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-print
              Value: 09237534
          Numbering:
            – Type: volume
              Value: 35
          Titles:
            – TitleFull: Annals of Oncology
              Type: main
ResultId 1